Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) (NCT06533579)
A Phase 1/2 Safety, Dose-finding, and Pharmacokinetics Study of VNX-101 Gene Therapy in Patients With Relapsed or Refractory CD19-Positive Hematologic Malignancies (SENTRY-CD19)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1/2, first-in-human, open-label, dose-escalating trial designed to assess the safety and efficacy of VNX-101 in patients with relapsed or refractory CD19-positive hematologic malignancies.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 13 Years to 90 Years
🧪 Interventions in This Study
- Dose Level 1, VNX-101 (GENETIC)
- Dose Level 2, VNX-101 (GENETIC)
- Dose Level 3, VNX-101 (GENETIC)
- Dose Level 4, VNX-101 (GENETIC)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- City of Hope — Duarte, California
- Valkyrie Clinical Trials — Los Angeles, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Mayo Clinic, Clinical Trials Referral Office — Jacksonville, Florida
- Mayo Clinic, Clinical Trials Referral Office — Rochester, Minnesota
- New York Medical College — Valhalla, New York
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center — Chapel Hill, North Carolina
- The Ohio State University Wexner Medical Center — Columbus, Ohio
- Oregon Health & Science University — Portland, Oregon
- TriStar BMT — Nashville, Tennessee
- University of Texas MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (908) 938-6019
Email: allen.reha@vironexis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in B-cell Acute Lymphoblastic Leukemia
- A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL) — Los Angeles, California
- A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia — Houston, Texas
- Venetoclax Plus Inotuzumab for B-ALL — Boston, Massachusetts
- Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients — Birmingham, Alabama
- Study Of KITE-753 in R/R B-Cell ALL — Houston, Texas
- A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia — New York, New York
Explore by condition: All B-cell Acute Lymphoblastic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.